Pathstone Holdings LLC Trims Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Pathstone Holdings LLC cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,518 shares of the company’s stock after selling 1,193 shares during the period. Pathstone Holdings LLC’s holdings in Medpace were worth $3,511,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of MEDP. Signaturefd LLC lifted its stake in shares of Medpace by 4.9% during the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after buying an additional 26 shares in the last quarter. Wealth Alliance lifted its position in shares of Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after acquiring an additional 27 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after acquiring an additional 32 shares during the period. Lindenwold Advisors INC grew its position in shares of Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV raised its stake in Medpace by 1.7% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock valued at $793,000 after purchasing an additional 39 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $337.75 on Monday. The stock has a market capitalization of $10.50 billion, a P/E ratio of 29.58, a PEG ratio of 1.89 and a beta of 1.37. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77. The business’s 50 day moving average is $340.14 and its two-hundred day moving average is $373.13.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent analyst reports. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Redburn Atlantic began coverage on shares of Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $380.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.